Perceived Benefits of MDMA-Assisted Psychotherapy beyond Symptom Reduction: Qualitative Follow-Up Study of a Clinical Trial for Individuals with Treatment-Resistant PTSD
William P. Barone, Jerome Beck, Michiko Mitsunaga-Whitten, Phillip Perl
Journal of Psychoactive Drugs March 8, 2019 DOI: 10.1080/02791072.2019.1580805 via OpenAlex
Summary
AI-generated from the abstractIn a long-term follow-up of a phase 2 clinical trial, veterans, firefighters, and police officers with chronic, treatment-resistant PTSD reported lasting personal benefits and enhanced quality of life one year after MDMA-assisted psychotherapy. Interviews with 19 of 24 participants were analyzed using interpretative phenomenological analysis. All participants described benefits that went beyond symptom reduction, such as improved relationships and well-being. The findings suggest that qualitative methods can capture treatment effects that standard symptom scales may miss. The authors discuss limitations of the study and recommend improved qualitative research protocols for future trials.
Study at a glance
| Characteristics | Qualitative study using interpretative phenomenological analysis Peer reviewed |
|---|---|
| Sample size | 19 |
| Population | Veterans, firefighters, and police officers with chronic, treatment-resistant PTSD |
| Intervention | MDMA-assisted psychotherapy |
| Duration | One-year follow-up |
| Topics | MDMA |
| Keywords | Thematic analysis Qualitative research Interpretative phenomenological analysis Clinical psychology |
| Citations | 63 |
| Key finding | All participants reported lasting personal benefits and enhanced quality of life beyond quantifiable symptom reduction one year after MDMA-assisted psychotherapy. |
Abstract
We present select findings from a long-term follow-up qualitative study of MDMA-assisted psychotherapy for veterans, firefighters, and police officers suffering from chronic, treatment-resistant PTSD. Semi-structured qualitative interviews were conducted at participants' one-year follow-up after a recently completed phase 2 clinical trial. Available interviews from 19 of 24 participants were analyzed. This qualitative analysis sought to complement, clarify, and expand upon the quantitative findings obtained from the Clinician Administered PTSD Scale (CAPS-IV) and supported by the Long-Term Follow-Up (LTFU) Questionnaire. Pertinent data from interview transcripts were coded and analyzed using an interpretative phenomenological analysis (IPA) methodological framework. We explore prominent thematic elements from participant accounts to better understand the outcomes experienced in this trial. All participants reported experiencing lasting personal benefits and enhanced quality of life that extend beyond quantifiable symptom reduction. We explore a range of treatment benefits beyond symptom reduction to highlight the utility of qualitative investigations of the process and effects of MDMA-assisted psychotherapy. Limitations and challenges encountered in conducting this study are discussed along with recommendations for improved qualitative research protocols in future clinical trials.